Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APEX1 | P27695 | 1/20 | 0.40 |
| ▸ | PNMT | P11086 | 5/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.30 |
| ▸ | GMNN | O75496 | 1/20 | 0.30 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15910262 | 0.76 | APEX1 (0.42) | APEX1PNMTMEN1GABRA1CYP2C19 | |
| SCHEMBL17377150 | 0.73 | APEX1 (0.43) | APEX1PNMTMEN1GABRA1CYP2C19 | |
| SCHEMBL18379152 | 0.72 | CD44 (0.43) | APEX1PNMTMEN1GABRA1CYP2C19 | |
| SCHEMBL21263695 | 0.71 | APEX1 (0.40) | APEX1PNMTMEN1GABRA1CYP2C19 | |
| SCHEMBL18368345 | 0.71 | APEX1 (0.40) | APEX1PNMTMEN1GABRA1CYP2C19 | |
| SCHEMBL15848407 | 0.69 | PNMT (0.41) | APEX1PNMTMEN1GABRA1CYP2C19 | |
| SCHEMBL19678871 | 0.67 | PNMT (0.37) | PNMT | |
| SCHEMBL3715448 | 0.67 | PTPRC (0.42) | APEX1PNMTGABRA1GABRB2ADORA1 | |
| SCHEMBL25363152 | 0.66 | APEX1 (0.38) | APEX1PNMTADORA1 | |
| SCHEMBL351180 | 0.66 | PNMT (0.43) | APEX1PNMTMEN1KMT2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10550123-B2 | Viral replication inhibitors | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2020-02-04 | — | — | US | disclosed |
| US-20190337954-A1 | VIRAL REPLICATION INHIBITORS | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2019-11-07 | — | — | US | disclosed |
| US-20140213586-A1 | VIRAL REPLICATION INHIBITORS | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2014-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140213586-A1 | VIRAL REPLICATION INHIBITORS | EIF2AK2, MAVS, ZC3HAV1 | APEX1 3008/4885PNMT 1286/4885MEN1 3390/4885 |
| US-20190337954-A1 | VIRAL REPLICATION INHIBITORS | EIF2AK2, MAVS, ZC3HAV1 | APEX1 3008/4885PNMT 1286/4885MEN1 3390/4885 |
| US-10550123-B2 | Viral replication inhibitors | EIF2AK2, MAVS, ZC3HAV1 | APEX1 3008/4885PNMT 1286/4885MEN1 3390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.